Yong, Shin Jie * and Halim, Alice and Halim, Michael and Long, Chiau Ming * and Goh, Khang Wen and Alfaresi, Mubarak and Alsalem, Zainab and Alwashmi, Ameen S S and Khamis, Faryal and Al Kaabi, Nawal A and Albayat, Amal and Alsheheri, Ahmed and Garout, Mohammed and Alsalman, Jameela and Alfaraj, Amal H and Alhajri, Mashael and Dhama, Kuldeep and Alburaiky, Lamees M and Alsanad, Ahlam H and AlShurbaji, Abdelmunim T and Rabaan, Ali A (2023) Experimental drugs in randomized controlled trials for long-COVID: what’s in the pipeline? A systematic and critical review. Expert Opinion on Investigational Drugs, 32 (7). pp. 655-667. ISSN 1744-7658
Full text not available from this repository. (Request a copy)Abstract
Introduction: Over three years have passed since the emergence of coronavirus disease 2019 (COVID-19), and yet the treatment for long-COVID, a post-COVID-19 syndrome, remains long overdue. Currently, there is no standardized treatment available for long-COVID, primarily due to the lack of funding for post-acute infection syndromes (PAIS). Nevertheless, the past few years have seen a renewed interest in long-COVID research, with billions of dollars allocated for this purpose. As a result, multiple randomized controlled trials (RCTs) have been funded in the quest to find an effective treatment for long-COVID. Areas covered: This systematic review identified and evaluated the potential of current drug treatments for long-COVID, examining both completed and ongoing RCTs. Expert opinion: We identified four completed and 22 ongoing RCTs, investigating 22 unique drugs. However, most drugs were deemed to not have high potential for treating long-COVID, according to three pre-specified domains, a testament to the ordeal of treating long-COVID. Given that long-COVID is highly multifaceted with several proposed subtypes, treatments likely need to be tailored accordingly. Currently, rintatolimod appears to have modest to high potential for treating the myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) subtype, LTY-100 and Treamid for pulmonary fibrosis subtype, and metformin for general long-COVID prevention.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | long-COVID; drug; post-COVID-19 syndrome; randomized clinical trial; treatment; |
| Subjects: | R Medicine > RA Public aspects of medicine R Medicine > RM Therapeutics. Pharmacology R Medicine > RS Pharmacy and materia medica |
| Divisions: | Others > Non Sunway Academics Sunway University > School of Medical and Life Sciences [formerly School of Healthcare and Medical Sciences until 2020] > Department of Medical Sciences |
| Depositing User: | Ms Yong Yee Chan |
| Related URLs: | |
| Date Deposited: | 09 Jul 2024 00:32 |
| Last Modified: | 09 Jul 2024 00:32 |
| URI: | http://eprints.sunway.edu.my/id/eprint/2766 |
Actions (login required)
 |
View Item |
